🇺🇸 FDA
Patent

US 8592386

Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis

granted A61KA61K31/7125A61K38/19

Quick answer

US patent 8592386 (Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis) held by Sarepta Therapeutics, Inc. expires Mon Nov 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sarepta Therapeutics, Inc.
Grant date
Tue Nov 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K31/7125, A61K38/19, A61K45/06, A61P